Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancerJeffrey How, Amir A. Jazaeri, Shrina Patel et al.|Gynecologic Oncology|2021Cited by 56
The tumor immune microenvironment shapes response to pembrolizumab in microsatellite instability-high endometrial cancerJeffrey How, Amir A. Jazaeri, Melinda S. Yates et al.|Gynecologic Oncology|2021Cited by 4
Abstract 1248: Predictors of innate resistance to pembrolizumab in patients with microsatellite instability-high endometrial cancerJeffrey How, Amir A. Jazaeri, Minghao Dang et al.|Cancer Research|2022Cited by 3
The use of pembrolizumab and lenvatinib combination therapy in endometrial cancer: an examination of toxicity and treatment efficacy in clinical practiceJeffrey How, Amir A. Jazaeri, Shrina Patel et al.|Gynecologic Oncology|2021Cited by 2
Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancerBrandon I. Ing, Amir A. Jazaeri, Derek Kuhl et al.|Gynecologic Oncology Reports|2023Cited by 2